On Thursday, Shares of Alibaba Group Holding Limited (NYSE:BABA), gained 2.36% to $75.11.
The Xen Project Collaborative Project hosted at The Linux Foundation declared Aliyun, the cloud computing partner of Alibaba Group Holding Limited (NYSE: BABA) is a new Advisory Board member.
Xen Project open source virtualization powers many of the largest clouds in production recently to deliver shared software, computing resources and data. Aliyun joins other Advisory Board members, counting Amazon Web Services, Rackspace and Verizon, that are also committed to the market and technical success of the hypervisor. Member involvement comprises financial support, technical contributions, and high-level policy guidance.
Xen Project software offers superior IT efficiencies, workload balancing, hyper-scalability and tight security by running VMs on a cloud service. Aliyun, with Xen virtualization will run many operating systems and applications off the same physical infrastructure. Aliyun has been contributing vulnerability fixes to the project for some time.
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally.
Shares of Valero Energy Corporation (NYSE:VLO), declined -0.73% to $69.68, during its last trading session, as U.S. oil prices tumbled more than 3 percent to a 6-1/2-year low under $42 a barrel on Thursday as data showing a big rise in key U.S. stockpiles intensified worries over a growing global glut, according to Reuters.
A rise in the dollar .DXY, after news of higher U.S. retail sales in July and strengthening employment data, added to the weight on oil. Reuters Reports
Valero Energy Corporation operates as an independent petroleum refining and marketing company in the United States, Canada, the Caribbean, the United Kingdom, and Ireland. It operates through two segments, Refining and Ethanol.
Finally, ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC), ended its last trade with -10.57% surge, and closed at $0.48.
ImmunoCellular Therapeutics declared that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary endpoint in the trial is overall survival, which the FDA and EU regulators have stated is the appropriate endpoint for registrational clinical studies in glioblastoma. Secondary endpoints comprise progression-free survival and safety, in addition to overall survival in the two pre-specified MGMT subgroups. Patient enrollment is anticipated to start in the late third quarter or early fourth quarter of 2015.
A Special Protocol Assessment is a written agreement between the sponsor company and the FDA on the design, clinical endpoints, size and statistical design of a clinical trial intended to form the primary basis of an efficacy claim in the marketing application, such as a biologic licensing application (BLA) or a new drug application (NDA). Final marketing approval depends upon the safety and efficacy results demonstrated in the phase 3 clinical program.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate comprises ICT-107, a dendritic cell (DC) vaccine that accomplished Phase II testing trials for the treatment of glioblastoma multiforme (GBM).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
